240 related articles for article (PubMed ID: 22253088)
1. Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.
Su JS; Woods SM; Ronen SM
NMR Biomed; 2012 Feb; 25(2):379-88. PubMed ID: 22253088
[TBL] [Abstract][Full Text] [Related]
2. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.
Venkatesh HS; Chaumeil MM; Ward CS; Haas-Kogan DA; James CD; Ronen SM
Neuro Oncol; 2012 Mar; 14(3):315-25. PubMed ID: 22156546
[TBL] [Abstract][Full Text] [Related]
3. Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts.
Romanska HM; Tiziani S; Howe RC; Günther UL; Gulzar Z; Lalani el-N
Neoplasia; 2009 Dec; 11(12):1301-8. PubMed ID: 20019838
[TBL] [Abstract][Full Text] [Related]
4. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Samartzis EP; Gutsche K; Dedes KJ; Fink D; Stucki M; Imesch P
Oncotarget; 2014 Jul; 5(14):5295-303. PubMed ID: 24979463
[TBL] [Abstract][Full Text] [Related]
5. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka SB; Singh SS; Dasmahapatra GP; Sausville EA; Roy KK
Mol Cancer Ther; 2003 Nov; 2(11):1093-103. PubMed ID: 14617782
[TBL] [Abstract][Full Text] [Related]
6. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Al-Saffar NM; Jackson LE; Raynaud FI; Clarke PA; Ramírez de Molina A; Lacal JC; Workman P; Leach MO
Cancer Res; 2010 Jul; 70(13):5507-17. PubMed ID: 20551061
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
8. Perifosine: update on a novel Akt inhibitor.
Gills JJ; Dennis PA
Curr Oncol Rep; 2009 Mar; 11(2):102-10. PubMed ID: 19216841
[TBL] [Abstract][Full Text] [Related]
9. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
[TBL] [Abstract][Full Text] [Related]
10. Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line.
Lin X; Zhang X; Wang Q; Li J; Zhang P; Zhao M; Li X
Neoplasma; 2012; 59(3):248-56. PubMed ID: 22329846
[TBL] [Abstract][Full Text] [Related]
11. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
12.
Andrejeva G; Gowan S; Lin G; Wong Te Fong AL; Shamsaei E; Parkes HG; Mui J; Raynaud FI; Asad Y; Vizcay-Barrena G; Nikitorowicz-Buniak J; Valenti M; Howell L; Fleck RA; Martin LA; Kirkin V; Leach MO; Chung YL
Autophagy; 2020 Jun; 16(6):1044-1060. PubMed ID: 31517566
[TBL] [Abstract][Full Text] [Related]
13. Probing the PI3K/Akt/mTor pathway using
Phyu SM; Tseng CC; Fleming IN; Smith TA
Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
16. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
Moestue SA; Dam CG; Gorad SS; Kristian A; Bofin A; Mælandsmo GM; Engebråten O; Gribbestad IS; Bjørkøy G
Breast Cancer Res; 2013 Feb; 15(1):R16. PubMed ID: 23448424
[TBL] [Abstract][Full Text] [Related]
17. Activation of HIF-1
Schoos A; Gabriel C; Knab VM; Fux DA
J Pharmacol Exp Ther; 2019 Sep; 370(3):480-489. PubMed ID: 31300611
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
Liu D; Hou P; Liu Z; Wu G; Xing M
Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758
[TBL] [Abstract][Full Text] [Related]
19. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
Guo JP; Coppola D; Cheng JQ
J Biol Chem; 2011 Oct; 286(43):37389-98. PubMed ID: 21908616
[TBL] [Abstract][Full Text] [Related]
20. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
Chiarini F; Del Sole M; Mongiorgi S; Gaboardi GC; Cappellini A; Mantovani I; Follo MY; McCubrey JA; Martelli AM
Leukemia; 2008 Jun; 22(6):1106-16. PubMed ID: 18385752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]